Tag Archives: risk evaluation mitigation strategies

FDA Publish Guidance on Risk Evaluation & Mitigation Strategies (REMS)

FDA Publish Guidance on Risk Evaluation & Mitigation Strategies (REMS)

This guidance is intended to address two topics pertaining to Medication Guides for drug and biological products:
• When FDA intends to exercise enforcement discretion regarding when a Medication Guide must be distributed with a drug or biological product dispensed to a healthcare professional for administration to a patient4 instead of being dispensed directly to the patient for self-administration or to the patient’s caregiver for administration to the patient.
• When a Medication Guide will be required as part of a risk evaluation and mitigation strategy (REMS).

For Assistance with Implementing a Risk Management Programme Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Regulators Publish Draft Guidance for industry on Risk Evaluation and Mitigation Strategies (REMS)

Regulators, FDA CDER Publish Draft Guidance for industry on Risk Evaluation and Mitigation Strategies (REMS)

full text here

This document provides guidance to industry on:

  • The format and content of a proposed risk evaluation and mitigation strategy (REMS), including REMS supporting documentation;
  • The content of assessments and proposed modifications of approved REMS;
  • What identifiers to use on REMS documents; and
  • How to communicate with FDA about a REMS.

The information on the content of a proposed REMS submission (section III of this document) also applies to proposed REMS that are voluntarily submitted by applicants or holders of approved applications (see section II.A of this document).

This guidance will address REMS elements and provisions that are broadly applicable to proposed REMS and to assessments and modifications of approved REMS. Other provisions,  such as those that pertain only to abbreviated new drug applications (ANDAs), or expanded information about REMS assessments and proposed modifications, will not be fully addressed, but will be the subject of future guidance.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

ida 100programme 515x64 LowRes Regulators Publish Draft Guidance for industry on Risk Evaluation and Mitigation Strategies (REMS)

Turn your Business Into an Investor Magnet

How to Write a Business Plan – Free E-Course

Get the secrets that turns your project into an investment magnet, 100% of our clients raise the finance they need to take their projects to the next stage, we will share these secrets with you. – Sign up for Free

Grow your Expertise for Free

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

First name

E-mail address

This guideline ap
recombinant vaccines for the prevention and treatment of infectious disease, and provides guidance on quality, non-clinical and clinical aspects.
ida consultants freestrategyconsultation 515x64 Regulators Publish Draft Guidance for industry on Risk Evaluation and Mitigation Strategies (REMS)